PAIN TRIGGERS
First-line stimulant medications fail to produce noticeable cognitive improvements or focus enhancements.
Medication efficacy wears off too early in the day, causing a crash.
SaaS· Adults diagnosed with ADHDPain 8.00/10WTP 7.0/10Market 8.0/10Validation 9.0Confidence 92%Jul 8, 2026
FocusTrack: ADHD Medication Trial Tracking & Symptom Journal
Adults with ADHD frequently face long, discouraging cycles of trial-and-error with medications (e.g., non-response or early crashes with Vyvanse/Adderall), lacking an objective, structured way to quantify symptom trends and share precise data with their doctors.
adhddata-managementhealthcaremobile-appproductivitysaasworkflow
1
STAGE 01 · PROBLEM
Is the problem real?
CANONICAL PROBLEM
Adults diagnosed with ADHD frequently experience non-responsiveness or adverse side effects from first-line stimulant medications (like Adderall and Vyvanse), leading to prolonged cycles of trial-and-error, disappointment, and ongoing executive dysfunction.
FREQUENCY
Multiple repeated complaints in the post and comments.
INTENSITY
Users explicitly describe existing tools as bloated/overkill and mention workaround behavior.
EVIDENCE
For those who didn’t respond to Adderall or Vyvanse, what ended up helping?
ADHD315
For those who didn’t respond to Adderall or Vyvanse, what ended up helping?
ADHD315
The right medication makes your coping mechanisms more effective, it doesn’t replace them.
commentThe best answer is both. Finding a good medication is important but it must be augmented by habit and awareness of your particular form of executive disfunction. The right medication makes your coping mechanisms more effective, it doesn’t replace them. IANAD etc etc The intensity of the traditional amphetamines effed me up in all sorts of ways. We ended up exploring the methylphenidate variants. YMMV but don’t be afraid to ask your doctor about second line therapies too.
2
STAGE 02 · CUSTOMER
Who feels this pain?
TARGET USERS
Adults diagnosed with ADHDA D H D Medication Trial Patients
Adults with ADHD tracking daily focus, medication efficacy, and side effects during the multi-month trial-and-error phase with their psychiatrist.
Context
Find an effective ADHD treatment plan (medication, dosage, or lifestyle changes) that reliably improves focus, reduces procrastination, and manages executive dysfunction.
Sought alternative prescription classes including methylphenidates, non-stimulants, and off-label antidepressants.
Using over-the-counter medications like pseudoephedrine to self-medicate or augment focus.
Current Workarounds
Crowdsourcing medical experiences from online peer communities to prepare for doctor appointments
Using standard notes apps or paper journals to track sporadic symptom patterns
Relying entirely on memory during monthly 15-minute psychiatric check-ins
3
STAGE 03 · MARKET
Where's the gap?
EXISTING SOLUTION GAPS
First-line ADHD medications (Adderall, Vyvanse) do not work universally for all neurodivergent individuals.
Medication alone fails to solve executive dysfunction without being paired with behavioral coping mechanisms and awareness.
The clinical trial-and-error process for finding psychiatric medication is discouraging, slow, and lacks clear predictive guidance.
OPPORTUNITY & VALUE
Why Now
Repeated complaints focus heavily on standard stimulants completely failing to improve cognitive function, and medication effects wearing off too early causing a clear crash phase.
Value Proposition
Unlike generic habit trackers or mood logs, FocusTrack specifically isolates medication dosage timelines, crash periods, and the interaction between physical medication response and executive functioning metrics.
Product Direction
A dedicated micro-journaling and tracking app optimized for ADHD brains that captures real-time data on focus, crash times, side effects, and behavioral coping mechanisms, automatically formatting it into a 1-page clinical summary for psychiatrists.
4
STAGE 04 · BUSINESS
How does it make money?
MONETIZATION
$9/moBilled monthly, cancel anytime during your trial process
Model
SaaS subscription
WILLINGNESS TO PAY
Users are spending significant money on doctor visits and non-responsive prescriptions while suffering from ongoing executive dysfunction; they are highly motivated to shorten the trial loop. The signals show they are already investing heavily in self-medication and alternative strategies.
5
STAGE 05 · EXECUTION
How do you ship it?
MVP PLAN
“From discouraging medication trial-and-error to clear data for your doctor in 6 weeks.”
A dedicated micro-journaling and tracking app optimized for ADHD brains that captures real-time data on focus, crash times, side effects, and behavioral coping mechanisms, automatically formatting it into a 1-page clinical summary for psychiatrists.
Core Features
Ultra-low-friction daily symptom check-ins optimized for low executive function
Crash-time logger to track when stimulant efficacy drops off during the day
Exportable PDF report with visual timelines and trends for psychiatric appointments
Weekly Roadmap
1
W1-W2
Core logging interface optimized for ADHD users is fully functional.
- •Build a 3-tap daily symptom, dose, and crash-time logging mechanism
- •Implement interactive local database storage for personal entries
- •Design simple visual dashboard for focus trends
2
W3-W4
Clinical PDF export engine and automated smart notification reminders completed.
- •Develop PDF generation engine formatting data into a 1-page psychiatric summary
- •Create micro-engagement push reminders designed to combat procrastination
- •Set up secure user authorization and onboarding flow
3
W5
Stripe integration finalized and private beta launched with 20 ADHD community members.
- •Integrate Stripe billing for subscription tiers
- •Recruit 20 active trial-and-error patients from ADHD subreddits for feedback
- •Fix bugs related to crash-time calculations and edge-case time zones
4
W6
Public launch with localized outreach to neurodivergent support networks.
- •Launch on Product Hunt and share clinical export templates on r/ADHD
- •Publish first anonymous user case study demonstrating an optimized doctor visit
- •Monitor initial conversion rates and weekly tracking retention metrics
Launch Strategy
Partner with ADHD coaches and target specific peer support communities (e.g., r/ADHD, r/Adderall, and X neurodivergent creators) by offering the clinical export feature for free.
RISKS & ASSUMPTIONS
Top Risks
Low compliance due to ADHD executive dysfunction
Users may forget or lack the activation energy to log their daily symptoms consistently, rendering the trend data incomplete.
Data parsing and privacy liabilities
Handling medication names and health symptoms requires strict data security measures to maintain user trust.
Psychiatrist dismissiveness
Doctors might dismiss patient-generated app data during appointments, decreasing the tool's perceived clinical utility.
6
STAGE 06 · DECISION
Should you build it?
NEED A CLEARER CALL?
Run an Investment Memo to get a structured Go / No-Go verdict, competitor landscape, unit economics, and a 90-day validation roadmap for this opportunity.
Generate an investment memoWhat this score means
This opportunity scores well above the median for ideas surfaced by MonetScope, with a validation sub-score of 9/10 against 3 independently sourced evidence signals. A "strong" rating in this band typically means the pain signal is consistent and recurring across multiple discussions, but one of the three pillars (severity, willingness to pay, or competitor weakness) is somewhat softer than top-tier opportunities. Founders evaluating this should focus customer discovery on the softest pillar first — confirming the gap before committing engineering time to a build.
Why this matters for SaaS founders
It sits at the intersection of "adhd", "data-management", "healthcare", which makes it relevant to a specific subset of founders rather than a generic horizontal opportunity. SaaS opportunities at this stage tend to win on the strength of their initial wedge — a single workflow that the target user runs every week, where the existing solution is either spreadsheets, a clunky incumbent feature, or a manual process they hate. The build cost is moderate; the distribution cost is everything. The MonetScope pipeline surfaces this category alongside other saas signals, which is why it appears here rather than in a generic "trending ideas" feed.
Scores are derived from real forum discussions across Reddit, Hacker News and X, weighted by evidence volume and signal quality. How scoring works
Frequently asked questions
Is "FocusTrack: ADHD Medication Trial Tracking & Symptom Journal" a real validated startup idea or just an AI-generated suggestion?
MonetScope does not generate ideas from a language model's imagination. Every opportunity on this site is anchored to specific source posts and comments from real public discussions — typically on Reddit, Hacker News, or X — where actual users describe the pain in their own words. The AI's role is structuring, scoring, and grouping those signals into a navigable opportunity, not inventing the problem.
How recent is the underlying data for adhd?
MonetScope's spider pipeline runs continuously and surfaces opportunities as new evidence accumulates. The "Updated" date in the header reflects the most recent re-scoring of this specific opportunity. Most saas opportunities visible in the public catalog draw from discussions in the last 30-60 days; older signals are de-prioritized because user pain shifts faster than most founders assume.
What's the difference between "overall score" and "validation score"?
Overall score is a composite across six dimensions — pain, urgency, willingness to pay, market size, defensibility, and execution ease — designed to give a single number for triage. Validation score is narrower: it asks "how cleanly does the same signal repeat across independent sources?" An opportunity can score high on overall but lower on validation when one or two large discussions dominate the evidence; conversely, validation can be high on a smaller-overall idea where the signal is consistent but the addressable market is modest.